Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by mollevi
Last modified by alainmange
Group name PlateformePP2I
Item Type Journal Article
Title IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding
Creator Ternant et al.
Author David Ternant
Author Christophe Arnoult
Author Martine Pugnière
Author Christine Dhommée
Author Daniel Drocourt
Author Eric Perouzel
Author Christophe Passot
Author Nadine Baroukh
Author Denis Mulleman
Author Gérard Tiraby
Author Hervé Watier
Author Gilles Paintaud
Author Valérie Gouilleux-Gruart
Abstract Because IgG1 allotypes might have different half-lives, their influence on infliximab (G1m17,1 allotype) pharmacokinetics was investigated in a group of spondyloarthritis patients. Infliximab was found to have a shorter half-life in patients homozygous for the G1m17,1 allotypes than in those carrying the G1m3 with no G1m1 (G1m3,-1) allotype. Because the neonatal FcR (FcRn) is involved in the pharmacokinetics of mAbs, the interaction of different IgG1 allotypes with FcRn was examined using cellular assays and surface plasmon resonance. G1m17,1 mAbs, such as infliximab and rituximab, were shown to bind more efficiently to FcRn and to be transcytosed better than the G1m3,-1 mAb cetuximab, which explains why infliximab is a better competitor for endogenous IgG1 in G1m3,-1 allotype-bearing patients. A set of four allotype variants of adalimumab (G1m17,1; G1m17,-1; G1m3,1; and G1m3,-1) was also tested for its binding to FcRn, revealing that the G1m3,1 variant, not present in commercial mAbs, binds more efficiently to FcRn and is transcytosed better than the other three variants, all of which are found in therapeutic mAbs.
Publication Journal of Immunology (Baltimore, Md.: 1950)
Volume 196
Issue 2
Pages 607-613
Date Jan 15, 2016
Journal Abbr J. Immunol.
Language eng
DOI 10.4049/jimmunol.1501780
ISSN 1550-6606
Library Catalog PubMed
Extra PMID: 26685205
Tags Antibodies, Monoclonal, author, Female, Flow Cytometry, Histocompatibility Antigens Class I, Humans, Immunoglobulin Allotypes, Immunoglobulin G, Infliximab, Male, original, Polymerase Chain Reaction, Polymorphism, Single Nucleotide, pp2i, Receptors, Fc, Spondylarthritis, Surface Plasmon Resonance, top
Date Added 2019/06/04 - 17:32:36
Date Modified 2020/01/14 - 18:45:40


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés